Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Metastatic Castration Resistant Prostate Cancer 1 Carcinoma, Renal Cell 1 Advanced Solid Tumor 1 Advanced Pancreatic Cancer 1 Advanced Cancer 1

Interventions

Doxorubicin 80 Ifosfamide 54 Radiotherapy 43 Filgrastim 41 Gemcitabine 38 Cyclophosphamide 34 Etoposide 26 Vincristine 24 Cisplatin 24 Docetaxel 23 pazopanib 21 Trabectedin 19 Carboplatin 17 pembrolizumab 15 Peripheral Blood Stem Cell Transplantation 14 eribulin 12 Mesna 12 Melphalan 12 Sorafenib 11 Sirolimus 11 Irinotecan 11 Granulocyte Colony-Stimulating Factor 11 Bevacizumab 11 Topotecan 10 Paclitaxel 10 Imatinib Mesylate 10 Chemotherapy, Adjuvant 10 pegfilgrastim 9 Temozolomide 9 Surgical Procedures, Operative 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Sarcoma × fluzoparib × Clear all

NCT05938374 2025-12-11

SPARE-03

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡